VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Emerging anti-CD20 monoclonal antibodies as first-line therapy in elderly CLL

At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the results of clinical trials of anti-CD20 monoclonal antibodies in combination with chloramubucil, obinutuzumab plus chloramubucil and ofatumumab plus chlorambucil, for first-line therapy in older patients with chronic lymphocytic leukemia (CLL).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter